| 摘要: |
| 目的 探讨成人头颈部横纹肌肉瘤组织中lin-28同源基因B（LIN28B）的表达及临床意义。方法 收集2009年1月至2015年12月我院22例年龄≥16周岁的头颈部横纹肌肉瘤患者的肿瘤组织，以及5例因其他实体肿瘤行手术切除患者的正常横纹肌组织（阴性对照）。采用免疫组织化学染色检测肿瘤组织中LIN28B蛋白的表达，并分析其表达与成人头颈部横纹肌肉瘤患者临床病理参数（性别、年龄、组织学类型、肿瘤大小、淋巴结转移、TNM分期、危险分组及颅底骨质破坏）和预后的关系。结果 免疫组织化学染色结果显示LIN28B蛋白在正常横纹肌组织中呈阴性表达，而在成人头颈部横纹肌肉瘤组织中呈阳性表达，阳性表现为细胞质染色呈棕黄色。根据组织学评分，12例成人头颈部横纹肌肉瘤患者的LIN28B表达呈低表达（0～3分），10例呈高表达（≥4分）。LIN28B在非胚胎性横纹肌肉瘤、肿瘤大小>5 cm患者的肿瘤组织中表达水平较高（P=0.020、0.030）；LIN28B表达与患者性别、年龄、淋巴结转移与否、TNM分期、危险分组及颅底骨质破坏与否无关（P均>0.05）。22例成人头颈部横纹肌肉瘤患者中位随访时间为78.4个月，中位无进展生存期及中位总生存期分别为12.4个月及17.9个月，5年无进展生存率及总生存率分别为11.4%及13.6%。LIN28B低表达成人头颈部横纹肌肉瘤患者的中位无进展生存期为17.9个月，长于高表达者的8.2个月（P=0.003）；LIN28B低表达者的中位总生存期为23.5个月，长于高表达者的10.9个月（P=0.009）。结论 LIN28B表达与成人头颈部横纹肌肉瘤肿瘤大小及组织学类型有关。LIB28B可能与成人头颈部横纹肌肉瘤的发生、发展有关，并且其高表达提示预后不良。 |
| 关键词: 头颈部肿瘤 横纹肌肉瘤 lin-28同源基因B 预后 |
| DOI：10.16781/j.0258-879x.2020.02.0129 |
| 投稿时间：2019-11-19修订日期：2020-01-06 |
| 基金项目:上海市卫生和计划生育委员会科研项目（20164Y0201）. |
|
| Expression and clinical significance of lin-28 homolog B in adult head and neck rhabdomyosarcoma |
| TIAN Shu1,LI Rui-chen1,HU Chun-yan2,ZHU Yi1,WANG Sheng-zi1,DING Hao1* |
(1. Department of Radiation Oncology, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai 201112, China;
2. Department of Pathology, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai 201112, China
*Corresponding author) |
| Abstract: |
| Objective To investigate the expression of lin-28 homolog B (LIN28B) in adult head and neck rhabdomyosarcoma and its clinical significance. Methods Tumor tissues from 22 patients with head and neck rhabdomyosarcoma (aged ≥ 16 years) treated in our hospital from January 2009 to December 2015 were collected. The normal striated muscle tissues of 5 patients who underwent surgical treatment for other solid tumors were used as negative controls. The expression of LIN28B protein in tumor tissues was detected by immunohistochemistry. The relationship between the expression of LIN28B and clinicopathological parameters of adult head and neck rhabdomyosarcoma was analyzed, including sex, age, histological type, tumor size, lymph node metastasis, TNM stage, risk group, and cranial base bony erosion. Meanwhile, the relationship between the expression of LIN28B and prognosis was evaluated. Results Immunohistochemistry showed that LIN28B protein was negative in normal striated muscle tissues, while LIN28B protein was positive in adult head and neck rhabdomyosarcoma. Brownish yellow in cytoplasm was considered as positive staining. According to the histological score, the expression of LIN28B was low in 12 adult head and neck rhabdomyosarcoma patients (0-3 points) and high in 10 patients (≥ 4 points). LIN28B presented high expression in patients with non-embryonal rhabdomyosarcoma and with tumor size>5 cm (P=0.020, 0.030). The expression of LIN28B was not correlated with sex, age, lymph node metastasis, TNM stage, risk group or cranial base bony erosion (all P>0.05). The median follow-up period of 22 adult head and neck rhabdomyosarcoma patients was 78.4 months. The median progression-free survival (PFS) and median overall survival (OS) of the whole cohort were 12.4 months and 17.9 months, respectively. The 5-year PFS rate and 5-year OS rate were 11.4% and 13.6%, respectively. The patients with low expression of LIN28B had longer median PFS than patients with high expression (17.9 months vs 8.2 months, P=0.003), so was the median OS (23.5 months vs 10.9 months, P=0.009). Conclusion The expression of LIN28B is related to tumor size and histological type in adult head and neck rhabdomyosarcoma. LIN28B may play a potential role in the occurrence and progress of this tumor, and its high expression indicates a poor prognosis. |
| Key words: head and neck neoplasms rhabdomyosarcoma lin-28 homolog B prognosis |
